Solutions

Clinical solutions

Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions

Consulting & Commercial

Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data

Case studies
Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

Technologies
Technology solutions from early phase through to post-marketing.
Sectors

Sectors

ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

Read more

Biotech Government and Public Health Medical Device Pharmaceuticals

Biotech
Developing transformative therapies requires a flexible approach.

ICON and You
Partners making a difference.
Therapeutics

Therapeutics

Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology

Cross-therapeutics

Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health

Obesity
A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

Therapeutics insights
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
Insights

Insights

Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel

Making sense of the rapidly changing biosimilars landscape
Strategies for adapting and achieving optimal market access

Building a comparative evidence base using network meta-analysis
Methods, implementation and reporting

From bottlenecks to breakthroughs
Human-centred strategies for faster study starts
News & Events

News & Events

ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

Read more

Press releases In the News Mediakit Awards Events Webinars Social media

Panel discussion: Flow cytometry in bioanalysis
26 March 2026. Register today.

ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Watch the webinar.
About ICON

About ICON

Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality

ICON for

Patients Volunteers Investigators Jobs & Careers Investors Suppliers

Sustainability, charity, inclusion and belonging
ICON Cares is our commitment to making a positive impact on our people, environment and our community.

ICON at a glance
Delivering successful outcomes across the clinical development lifecycle.

Careers
Investors
Contact
日本語
简体中文

Home
News & Events
Social media

Social media

Showing 109 - 120 of 1038 results for "*"

The EU Joint Clinical Assessment (#JCA), launched in 2025, is reshaping how oncology and #ATMP trials are designed and assessed across Europe. With 27 EU countries plus Norway, Switzerland, Ukraine and the UK now sharing...

19 Feb

View post

View webpage

ICON Plc

New analyses show that well-implemented DHTs can: - Reduce trial timelines by 3–5 months - Decrease enrollment requirements by up to 16% - Lower protocol amendment risk - Deliver meaningful ROI in both Phase II and Phase...

19 Feb

View post

View webpage

ICON Plc

19 Feb

View post

View webpage

ICON Plc

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

18 Feb

View post

View webpage

ICON Plc

18 Feb

View post

View webpage

ICON Plc

Come along to Rüdiger Kaspera's Learning Lab at ASCPT, where he’ll dive into science and risk based strategies for designing oligonucleotide First‑in‑Human studies - covering toxicity, study design, PK/PD, population se...

18 Feb

View post

View webpage

ICON Plc

Patient led organisations are shaping scientific and regulatory strategy in ultra rare diseases. Join our live panel as we bring together leaders whose work has contributed to gene therapies, accelerated approvals and ...

18 Feb

View post

View webpage

ICON Plc

How do patient-led organisations help bring therapies to families faster? Our live webinar gathers relentless leaders to explore real world examples of patient-led innovation reshaping drug development and regulatory str...

18 Feb

View post

View webpage

ICON Plc

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

17 Feb

View post

View webpage

ICON Plc

17 Feb

View post

View webpage

ICON Plc

Understanding how clinical trials are delivered starts with clarity on the roles that shape them. Our latest blog explains how sponsors set the research agenda and retain oversight, how CROs manage operational delivery...

16 Feb

View post

View webpage